Short answer
Mirum Pharmaceuticals, Inc. (MIRM) filed an 8-K current report with the SEC on October 26, 2026 reporting Item 8.01 (Other Events). Positive Cohort 2 results in 25 children support expanding ATEBRIOZ approval to ages 6 to <12.
Mirum Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Positive Cohort 2 results in 25 children support expanding ATEBRIOZ approval to ages 6 to <12
- HO lesion volume fell 8.09 cm³ with zilurgisertib versus a 9.14 cm³ increase with placebo, nominal p=0.003
- No zilurgisertib-treated patients developed new HO lesions versus 1 placebo patient, 7.7%
- CAJIS joint-mobility scores improved 0.80 points with treatment versus 0.09 with placebo
- Planned sNDA submission in first half of 2027 creates a regulatory catalyst; Cohort 3 is enrolling ages 2 to <12
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Mirum Pharmaceuticals, Inc. 8-K filings
Get the next MIRM 8-K as it lands
Follow MIRM for push alerts, or ask the research agent what this filing means.